Drug discovery remains a slow and fragmented process, with an alarming failure rate of 90% to 95%. It often takes over a decade and up to $1 billion to bring a single successful drug to market. While generative AI has offered new solutions, Stanford researchers have advanced the field with autonomous AI “scientist” agents that simulate the entire drug development lifecycle. Led by James Zou, these thousands of AI agents operate within a unified framework, handling discovery, safety testing, clinical trial design, and more, preserving project continuity and context. The hierarchical system uses a chief scientist agent to oversee task delegation among specialized agent teams. Data integration spans from genomics and FDA chemistry to trial databases, enabling sophisticated synthesis and analysis powered by models like Claude and specialized fine-tuned versions. Zou’s startup, Human Intelligence, built on this research, is currently valued near $1 billion. At VB Transform 2026, Zou will unveil strategies for managing complex multi-agent workflows, transforming enterprise data to be agent-native, and employing human auditing for reliable AI outputs. Another event highlights how Zillow boosted engineering productivity by 40% through trustworthy agentic AI foundations. Interested leaders can register for VB Transform 2026 and inquire about complimentary passes for senior tech executives.
Back
